Filing Details
- Accession Number:
- 0001127602-18-010230
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-03-05 18:54:28
- Reporting Period:
- 2018-03-01
- Accepted Time:
- 2018-03-05 18:54:28
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 882095 | Gilead Sciences Inc | GILD | Biological Products, (No Disgnostic Substances) (2836) | 943047598 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1190578 | C John Martin | Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 | Executive Chairman | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-03-01 | 50,000 | $23.60 | 3,067,762 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-03-01 | 16,902 | $77.84 | 3,050,860 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-03-01 | 26,575 | $78.95 | 3,024,285 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-03-01 | 6,523 | $79.49 | 3,017,762 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-qualified Stock Option (Right to Buy) | Disposition | 2018-03-01 | 50,000 | $0.00 | 50,000 | $23.60 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 450,000 | 2019-01-21 | No | 4 | M | Direct |
Footnotes
- The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- Sale prices reported for the transactions reported here range from $77.33 to $78.32. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- Sale prices reported for the transactions reported here range from $78.35 to $79.35. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- Sale prices reported for the transactions reported here range from $79.36 to $79.74. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Billionaire Hedge Funds
